Compare OPRT & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPRT | SENS |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.0M | 301.2M |
| IPO Year | 2019 | 2014 |
| Metric | OPRT | SENS |
|---|---|---|
| Price | $5.84 | $5.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.00 | ★ $18.38 |
| AVG Volume (30 Days) | 497.6K | ★ 867.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.18 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $956,685,000.00 | $16,389,000.00 |
| Revenue This Year | $32.79 | $74.15 |
| Revenue Next Year | $4.47 | $58.60 |
| P/E Ratio | $118.00 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $4.03 | $0.41 |
| 52 Week High | $7.33 | $8.75 |
| Indicator | OPRT | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 40.65 |
| Support Level | $5.06 | $5.40 |
| Resistance Level | $6.19 | $5.94 |
| Average True Range (ATR) | 0.25 | 0.39 |
| MACD | 0.07 | -0.13 |
| Stochastic Oscillator | 80.09 | 15.81 |
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.